cells

COMBINING TO CURE®

Arcus is at the forefront of designing precision combinations in the pursuit of cures for patients living with cancer.

We’re combining
therapeutic strategies

to activate the immune system to recognize and eradicate cancer, which we believe has the potential to achieve cures that have eluded medicine for decades.

We’re combining
our expertise

across scientific disciplines to discover innovative, best-in-class medicines and to design combination therapies guided by specific biologic profiles of cancer.

We’re combining with the medical community

and with patients and their caregivers to facilitate participation in our clinical trials and bring breakthrough medicines to patients faster.

Arcus clinical trials are currently enrolling

Join forces with us on our mission to defeat cancer

Read our latest press releases and announcements

CLINICAL PIPELINE

Indication View
Molecule View
Indication
Study
Line & Regimena,b,c
Phase 1
Phase 1b
Randomized/
Phase 2
Pivotal/
Phase 3
Indication:

NSCLC

Line & Regimena,b,c :
WT 1L, PD-L1 ≥ 50%
dom + zim ± etruma
Phase 1
Phase 1b
Randomized/
Phase 2
Pivotal/
Phase 3
Line & Regimena,b,c :
WT 1L, PD-L1 ≥ 50%
dom + zim vs. zim vs. chemo
Phase 1
Phase 1b
Randomized/
Phase 2
Pivotal/
Phase 3
Line & Regimena,b,c :
Stage III, unresectable, PD-L1≥1%
dom + durvalumab vs. durvalumab
Phase 1
Phase 1b
Randomized/
Phase 2
Pivotal/
Phase 3
Line & Regimena,b,c :
1L
dom + zim + chemo vs. pembro + chemo
Phase 1
Phase 1b
Randomized/
Phase 2
Pivotal/
Phase 3
Indication:

mCRPC

Line & Regimena,b,c :
2L+
etruma + zim + doce
Phase 1
Phase 1b
Randomized/
Phase 2
Pivotal/
Phase 3
Indication:

CRC

Line & Regimena,b,c :
3L
etruma + zim + FOLFOX* vs. rego
Phase 1
Phase 1b
Randomized/
Phase 2
Pivtotal/
Phase 3
Indication:

PDAC

Line & Regimena,b,c :
2L
quemli + zim + gem/nab-pac
Phase 1
Phase 1b
Randomized/
Phase 2
Pivtotal/
Phase 3
Indication:

UPPER GI

Line & Regimena,b,c :
2L+
dom + zim
Phase 1
Phase 1b
Randomized/
Phase 2
Pivtotal/
Phase 3
Line & Regimena,b,c :
1L
dom + zim + chemo vs. nivo + chemo
Phase 1
Phase 1b
Randomized/
Phase 2
Pivotal/
Phase 3
Indication:

Advanced Malignancies

Line & Regimena,b,c :
2L+
AB521
Phase 1
Phase 1b
Randomized/
Phase 2
Pivotal/
Phase 3
Line & Regimena,b,c :
AB308 + zim
Phase 1
Phase 1b
Randomized/
Phase 2
Pivtotal/
Phase 3
Indication:

Healthy Participants

Line & Regimena,b,c :
AB521
Phase 1
Phase 1b
Randomized/
Phase 2
Pivotal/
Phase 3
Moleculea,b,c
Indication
Study
Line & Regimen
Phase 1
Phase 1b
Phase 2
Phase 3
Moleculea,b,c :

Domvanalimab
(DOM)

FC-SILENT ANTI-TIGIT ANTIBODY

Indication:

UPPER GI

Line & Regimen:
dom + zim + FOLFOX*
Phase 1
Phase 1b
Phase 2
Phase 3
Indication:

UPPER GI

Line & Regimen:
2L+
dom + zim
Phase 1
Phase 1b
Phase 2
Phase 3
Indication:

UPPER GI

Line & Regimen:
1L
dom + zim + chemo vs. nivo + chemo
Phase 1
Phase 1b
Phase 2
Phase 3
Indication:

NSCLC

Line & Regimen:
1L
dom + zim ± etruma
Phase 1
Phase 1b
Phase 2
Phase 3
Indication:

NSCLC

Line & Regimen:
WT 1L, PD-L1 ≥ 50%
dom + zim vs. zim vs. chemo
Phase 1
Phase 1b
Phase 2
Phase 3
Indication:

NSCLC

Line & Regimen:
Stage III, unresectable, PD-L1≥1%
dom + durvalumab vs. durvalumab
Phase 1
Phase 1b
Phase 2
Phase 3
Indication:

NSCLC

Line & Regimen:
1L
dom + zim + chemo vs. pembro + chemo
Phase 1
Phase 1b
Phase 2
Phase 3
Moleculea,b,c :

AB308

FC-ENABLED ANTI-TIGIT ANTIBODY

Indication:

Advanced Malignancies

Line & Regimen:
1L
AB308 + zim
Phase 1
Phase 1b
Phase 2
Phase 3
Moleculea,b,c :

Quemliclustat

CD73 Inhibitor Small Molecule

Indication:

PDAC

Line & Regimen:
1L
quemli + zim + gem/nab-pac
Phase 1
Phase 1b
Phase 2
Phase 3
Indication:

PDAC

Line & Regimen:
2L
quemli + zim + gem/nab-pac
Phase 1
Phase 1b
Phase 2
Phase 3
Moleculea,b,c :

Etrumadenant
(ETRUMA)

Dual A2a/A2b Adenosine Receptor Antagonist Small Molecule

Indication:

CRPC

Line & Regimen:
2L
etruma + zim + doce
Phase 1
Phase 1b
Phase 2
Phase 3
Indication:

CRC

Line & Regimen:
2L
etruma + zim + FOLFOX* vs. FOLFOX*
Phase 1
Phase 1b
Phase 2
Phase 3
Indication:

CRC

Line & Regimen:
3L
etruma + zim + FOLFOX* vs. rego
Phase 1
Phase 1b
Phase 2
Phase 3
Indication:

CRC

Line & Regimen:
>3L
etruma combinations
Phase 1
Phase 1b
Phase 2
Phase 3
Indication:

NSCLC

Line & Regimen:
1L
dom + zim ± etruma
Phase 1
Phase 1b
Phase 2
Phase 3
Moleculea,b,c :

AB521

HIF-2𝛂 Inhibitor

Indication:

Healthy Participants

Line & Regimen:
1L
AB521
Phase 1
Phase 1b
Phase 2
Phase 3
Indication:

Advanced Malignancies, Including RCC

Line & Regimen:
2L+
AB521
Phase 1
Phase 1b
Phase 2
Phase 3


Etrumadenant: Dual A2aR/A2bR Antagonist Small Molecule
Quemliclustat: CD73 Inhibitor Small Molecule
Domvanalimab: TIGIT mAb
Zimberelimab: PD-1 mAb

These molecules and their uses are investigational, have not been proven to be safe, and have not been approved by the U.S. Food and Drug Administration.

ABBREVIATIONS:
atezo: atezolizumab; bev: bevacizumab; carbo/pem: carboplatin/pemetrexed; doce: docetaxel; dom: domvanalimab; enza: enzalutamide; etruma: etrumadenant; gem/nab-pac: gemcitabine/nab-paclitaxel; nivo: nivolumab; pembro: pembrolizumab; PLD: pegylated liposomal doxorubicin; quemli: quemliclustat; rego: regorafenib; SOC: standard of care; zim: zimberelimab;

CRC=colorectal cancer; CRPC=castrate-resistant prostate cancer; GI=gastrointestinal; NSCLC=non-small cell lung cancer; PDAC=pancreatic ductal adenocarcinoma; RCC=renal cell carcinoma

PARTNERSHIPS & COLLABORATIONS:

gilead logo (a) In May 2020, Arcus and Gilead announced a 10-year partnership to co-develop and co-commercialize next-generation cancer immunotherapies. The parties will co-develop Gilead-optioned programs globally, and will co-commercialize in the U.S., with Gilead commercializing outside of the U.S., subject to the rights of Arcus’s existing partners for such programs.

taiho logo (b) In September 2017, Arcus and Taiho announced an option and license agreement. Taiho has an option to Arcus’s programs arising during the 5-year term for Japan and certain other Asian territories (excluding China).

Astra Zeneca logo (c) Arcus and AstraZeneca are collaborating on PACIFIC-8, a registrational Phase 3 clinical trial, to evaluate domvanalimab plus durvalumab (Imfinzi®) in unresectable Stage 3 NSCLC with curative intent, where durvalumab is standard of care.

*+/- biologic


Etrumadenant: Dual A2aR/A2bR Antagonist Small Molecule
Quemliclustat: CD73 Inhibitor Small Molecule
Domvanalimab: TIGIT mAb
Zimberelimab: PD-1 mAb

These molecules and their uses are investigational, have not been proven to be safe, and have not been approved by the U.S. Food and Drug Administration.

ABBREVIATIONS:
atezo: atezolizumab; bev: bevacizumab; carbo/pem: carboplatin/pemetrexed; doce: docetaxel; dom: domvanalimab; enza: enzalutamide; etruma: etrumadenant; gem/nab-pac: gemcitabine/nab-paclitaxel; nivo: nivolumab; pembro: pembrolizumab; PLD: pegylated liposomal doxorubicin; quemli: quemliclustat; rego: regorafenib; SOC: standard of care; zim: zimberelimab

CRC=colorectal cancer; CRPC=castrate-resistant prostate cancer; GI=gastrointestinal; NSCLC=non-small cell lung cancer; PDAC=pancreatic ductal adenocarcinoma; RCC=renal cell carcinoma

PARTNERSHIPS & COLLABORATIONS:

gilead logo (a) In May 2020, Arcus and Gilead announced a 10-year partnership to co-develop and co-commercialize next-generation cancer immunotherapies. The parties will co-develop Gilead-optioned programs globally, and will co-commercialize in the U.S., with Gilead commercializing outside of the U.S., subject to the rights of Arcus’s existing partners for such programs.

taiho logo (b) In September 2017, Arcus and Taiho announced an option and license agreement. Taiho has an option to Arcus’s programs arising during the 5-year term for Japan and certain other Asian territories (excluding China).

Astra Zeneca logo (c) Arcus and AstraZeneca are collaborating on PACIFIC-8, a registrational Phase 3 clinical trial, to evaluate domvanalimab plus durvalumab (Imfinzi®) in unresectable Stage 3 NSCLC with curative intent, where durvalumab is standard of care.

*+/- biologic

DISCOVERY PIPELINE

Immuno-Oncology Target

molecule icon

Anti-CD39

Exo-nucleotidase

CD39 is a key enzyme in removing ATP from the tumor microenvironment; increased ATP may enhance the adaptive immune response against tumors.1

Additional undisclosed targets.

Cancer Cell Intrinsic Target

molecule icon

AXL Inhibitor

Tyrosine kinase

AXL overexpression is associated with tumor resistance to chemotherapy and immunotherapy drugs.2

Additional undisclosed targets.

References: 1. Moesta et al. Targeting CD39 in Cancer. Nature Reviews Immunology volume 20, pages739–755 (2020). 2. Axelrod HD, Valkenburg KC, Amend SR, et al. AXL is a putative tumor suppressor and dormancy regulator in prostate cancer. Mol Cancer Res. 2019;17(2):356-369.